STA
BPMC

Summit Trail Advisors’s Blueprint Medicines BPMC Stock Holding History

Summit Trail Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10
Closed -$1K – 589
2017
Q4 		$1K Buy
+10
New +$704 ﹤0.01% 1758

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Summit Trail Advisors's BPMC Position: Q1 2018 in Review

Summit Trail Advisors sold out of Blueprint Medicines (BPMC) in Q1 2018, closing a stake of 10 shares — an estimated $1K sold.

Summit Trail Advisors first reported a position in BPMC in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 175 funds tracked by Wall St. Rank hold BPMC as of Q1 2018.

  • Summit Trail Advisors reported no remaining Blueprint Medicines position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 10 Blueprint Medicines shares in Q1 2018, an estimated $1K.
  • Summit Trail Advisors first reported a position in Blueprint Medicines in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Blueprint Medicines position peaked at $1K in Q4 2017.
  • 175 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.